CA2161256C - Methodes et compositions pour le traitement des troubles gastriques grace a du (-)-pantoprazole optiquement pur - Google Patents

Methodes et compositions pour le traitement des troubles gastriques grace a du (-)-pantoprazole optiquement pur Download PDF

Info

Publication number
CA2161256C
CA2161256C CA002161256A CA2161256A CA2161256C CA 2161256 C CA2161256 C CA 2161256C CA 002161256 A CA002161256 A CA 002161256A CA 2161256 A CA2161256 A CA 2161256A CA 2161256 C CA2161256 C CA 2161256C
Authority
CA
Canada
Prior art keywords
pantoprazole
pharmaceutically acceptable
amount
treatment
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002161256A
Other languages
English (en)
Other versions
CA2161256A1 (fr
Inventor
Nancy M. Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of CA2161256A1 publication Critical patent/CA2161256A1/fr
Application granted granted Critical
Publication of CA2161256C publication Critical patent/CA2161256C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002161256A 1993-04-27 1994-04-25 Methodes et compositions pour le traitement des troubles gastriques grace a du (-)-pantoprazole optiquement pur Expired - Fee Related CA2161256C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5431893A 1993-04-27 1993-04-27
US08/054,318 1993-04-27
PCT/US1994/004543 WO1994024867A1 (fr) 1993-04-27 1994-04-25 Procedes et compositions permettant de traiter des troubles gastriques au moyen de pantoprazole (-) optiquement pur

Publications (2)

Publication Number Publication Date
CA2161256A1 CA2161256A1 (fr) 1994-11-10
CA2161256C true CA2161256C (fr) 2004-06-29

Family

ID=21990236

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002161256A Expired - Fee Related CA2161256C (fr) 1993-04-27 1994-04-25 Methodes et compositions pour le traitement des troubles gastriques grace a du (-)-pantoprazole optiquement pur

Country Status (6)

Country Link
US (4) US5888535A (fr)
EP (1) EP0695123A4 (fr)
JP (1) JPH08509736A (fr)
AU (2) AU6713194A (fr)
CA (1) CA2161256C (fr)
WO (1) WO1994024867A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161256C (fr) * 1993-04-27 2004-06-29 Nancy M. Gray Methodes et compositions pour le traitement des troubles gastriques grace a du (-)-pantoprazole optiquement pur
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
WO1999056748A1 (fr) * 1998-05-05 1999-11-11 Sepracor Inc. Compositions de demethylpantoprazole et procedes les concernant
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US8287554B2 (en) 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
EP1575941B1 (fr) 2002-12-06 2012-04-11 Nycomed GmbH Procédé de préparation de (S)-pantoprazole
PT1578742E (pt) 2002-12-06 2013-01-24 Nycomed Gmbh Processo para preparar compostos activos opticamente puros
US20060235053A1 (en) * 2003-05-06 2006-10-19 Atlanta Pharma Ag Agents for the treatment of lower abdominal disorders
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2005011691A1 (fr) * 2003-07-31 2005-02-10 Altana Pharma Ag Liaison amelioree du pantoprazole et de la pompe a protons
US20070027189A1 (en) * 2003-09-18 2007-02-01 Altana Pharma Ag Use of known active ingredients as radical scavengers
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005074930A1 (fr) * 2004-01-28 2005-08-18 Altana Pharma Ag Combinaisons pharmaceutiques de (s) -pantoprazole avec nsaid ou des corticosteroides
WO2005074898A2 (fr) * 2004-01-28 2005-08-18 Altana Pharma Ag Nouvelle combinaison pour le traitement d'helicobacter pylori
US20080234326A1 (en) * 2004-01-28 2008-09-25 Altana Pharma Ag Novel Salts of Pantoprazole and (S) - Pantoprazole
WO2005074932A1 (fr) * 2004-01-28 2005-08-18 Altana Pharma Ag Utilisation de (s)-pantoprazole magnesium pour le traitement de troubles des voies respiratoires
WO2005074931A1 (fr) * 2004-01-28 2005-08-18 Altana Pharma Ag Produits composes pharmaceutiques comprenant (s)-pantoprazole
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
CN101250181B (zh) * 2008-03-26 2011-04-27 江苏奥赛康药业有限公司 S-泮托拉唑钠
GB2471619B (en) * 2008-03-31 2012-10-31 Council Scient Ind Res Method for the simultaneous preparation of 3-acetoxy-17-acetamdo-16-formyl-androst-5,16-diene and 3-acetoxy-2'-chloro-5-androsteno[17,6-B]pyridine
EP3225484B1 (fr) 2016-03-31 2018-10-24 Ford Global Technologies, LLC Procédé de commande de la transition d'un véhicule automobile vers et hors d'un mode de fonctionnement en roue libre

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
CA2161256C (fr) * 1993-04-27 2004-06-29 Nancy M. Gray Methodes et compositions pour le traitement des troubles gastriques grace a du (-)-pantoprazole optiquement pur

Also Published As

Publication number Publication date
US20040142032A1 (en) 2004-07-22
WO1994024867A1 (fr) 1994-11-10
AU6904498A (en) 1998-07-16
US6953808B2 (en) 2005-10-11
EP0695123A4 (fr) 1996-09-11
US20010008899A1 (en) 2001-07-19
US5888535A (en) 1999-03-30
US20030086968A1 (en) 2003-05-08
EP0695123A1 (fr) 1996-02-07
CA2161256A1 (fr) 1994-11-10
JPH08509736A (ja) 1996-10-15
AU6713194A (en) 1994-11-21

Similar Documents

Publication Publication Date Title
CA2161256C (fr) Methodes et compositions pour le traitement des troubles gastriques grace a du (-)-pantoprazole optiquement pur
US20050222211A1 (en) S(-)rabeprazole compositions and methods
US20030008903A1 (en) R-lansoprazole compositions and methods
US20020019420A1 (en) Methods and compositions for treating gastric disorders using optically pure (+)-pantoprazole
EP1056457A1 (fr) Compositions de s-lansoprazole et procedes d'utilisation
US6174902B1 (en) R-rabeprazole compositions and methods
AU2003204192B2 (en) Methods and Compositions for Treating Gastric Disorders Using Optically Pure (-) Pantoprazole
AU3870599A (en) R-rabeprazole compositions and methods
CA2337886C (fr) Compositions pharmaceutiques contenant de l'hydroxylansoprazole et utilisations de ces dernieres
AU2003257509A1 (en) S-rabeprazole compositions and methods
AU2003268822A1 (en) R-raberprazole compositions and methods

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed